Drug Trial Radar · NCT03032510
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
Last checked: Nov 20, 2026Latest source record: Jan 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,205
Actual
Start
Jan 2017
Primary completion
Dec 2017
Study completion Jan 2018
Sponsor
- Lead sponsor
- Tetraphase Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
Conditions
- Complicated Urinary Tract Infections
Interventions
EravacyclineDrug
ErtapenemDrug
PlaceboDrug
LevofloxacinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI VisitTime frame: End of Infusion
- Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) VisitTime frame: TOC visit (14-17 days after randomization)
Locations
69 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Fullerton, California
Site not named
Los Angeles, California
Site not named
Torrance, California
Site not named
Coral Gables, Florida
Site not named
Doral, Florida
Site not named
Miami, Florida
Site not named
Columbus, Georgia
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Baytown, Texas
Site not named
Graz, Austria
Site not named
Linz, Austria
Site not named
Salzburg, Austria
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Razgrad, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Smyadovo, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Veliko Tarnovo, Bulgaria
Site not named
Tallinn, Estonia
Site not named
Tartu, Estonia
Site not named
Võru, Estonia
Site not named
K'ut'aisi, Georgia
Site not named
Tbilisi, Georgia
Site not named
Baja, Hungary
Site not named
Budapest, Hungary
Site not named
Miskolc, Hungary
Site not named
Nagykanizsa, Hungary
Site not named
Nyíregyháza, Hungary
Site not named
Sopron, Hungary
Site not named
Szentes, Hungary
Site not named
Tatabánya, Hungary
Site not named
Jelgava, Latvia
Site not named
Riga, Latvia
Site not named
Valmiera, Latvia
Site not named
Chisinau, Moldova
Site not named
Brasov, Romania
Site not named
Bucharest, Romania
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.